Do not stop B12 intake cold turkey when you change formulations

The most frequently reported adverse effects are gastrointestinal and typically occur during treatment initiation or dose escalation: Nausea (very common): Usually mild to moderate and diminishing over time Diarrhoea (very common): Potentially contributing to dehydration Vomiting (common): Particularly during early treatment phases Constipation (common): Due to delayed gastric emptying Abdominal pain and dyspepsia (common): May affect eating and drinking patterns Decreased appetite (very common): A therapeutic effect that may inadvertently reduce fluid intake Other notable side effects include: Injection site reactions (erythema, pruritus, swelling) Fatigue and dizziness, which may be exacerbated by dehydration Hypoglycaemia, particularly when used with insulin or sulfonylureas (doses of these medications may need to be reduced when starting tirzepatide) Increased heart rate (modest elevation of 2-4 beats per minute) Gallbladder problems including gallstones and inflammation Potential worsening of diabetic retinopathy in patients with pre-existing disease According to NICE guidance , patients should be counselled about these expected side effects before initiating treatment

Here, some categories and what the science shows: Weight and appetite-related peptides These are the only peptides consistently shown to support meaningful fat loss: Semaglutide (Wegovy, Ozempic) Tirzepatide (Zepbound, Mounjaro) These medications are known as GLP-1 receptor agonists (tirzepatide also acts on GIP)
Supporting thyroid function does not mean chasing numbers or applying one-size-fits-all solutions
The NL-GHK-Cu peptide, which is a safe and non-toxic peptide, shows the ability to activate multiple pathways allowing therapy that alleviates symptoms of respiratory diseases, especially of the lungs